Month: June 2021

THE BID COMMITTEE UNANIMOUSLY RECOMMENDS THE SHAREHOLDERS TO ACCEPT THE OFFER FROM HANOVER. This statement is made by the bid committee of the board of directors of ZetaDisplay AB (publ) (”ZetaDisplay”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the ”Takeover Rules”). The Offer Today, 28 June 2021 Hanover Active Equity Fund II S.C.A. SICAV-RAIF through Alpha Acquisition AB (the ”Offeror”) announced a public offer of SEK 27 in cash per share to the shareholders of ZetaDisplay (the ”Offer”). The Offer price represents a premium of:68 per cent in relation to the closing price for ZetaDisplay’s ordinary shares on Nasdaq Stockholm on 30 March 2021, which was the last day of trading prior to ZetaDisplay’s announcement of a review of strategic alternatives for ZetaDisplay; 27 per cent in relation to the closing price for...

Paris, June 28, 2021 Ramsay Santé tops up its collateral trust (created in 2018), making it one of the largest (€186 m) on the French market and the first to be linked to ESG criteria. After renegotiating its syndicated debt this April with a TLB indexed to the company’s ESG performance (see press release: https://ramsaysante.fr/sites/default/files/pdf/cp-2021-04-22-ramsay-sante-refinancement-dette-syndiquee.pdf), Ramsay Santé, one of the leaders of the private hospitalisation and primary care in Europe, is now continuing its refinancing and sustainable commitment drive with this second financial instrument indexed to environmental objectives. Immobilière de Santé, the main holding company for the Ramsay Santé group’s long-term investments in securities and/or real-estate assets, signed a contract for an additional €98m loan. Arranged...

Stockholm, Sweden –– June 28, 2021 — Hoylu, a leader in visual collaboration solutions for distributed teams, introduces a seamless way to collaborate on and visualize any Agile project. Most product development teams use some form of Agile to manage how they plan and execute projects. However, as we shift away from in-person work it’s become a lot harder to visualize sprints, product roadmaps, backlogs, and other Agile work streams. Product owners spend hours going through lists of tickets in issue tracking systems like Jira and VersionOne to map out dependencies and prioritize deliverables. Scrum teams can spend days figuring out project scope and locking down commitments. With today’s release, Hoylu empowers hybrid and distributed Agile teams to gain in-person levels of engagement and collaboration. Agile teams can bring back...

Two of the Largest Global Insurance Companies Select Award-Winning CCM Solution Quadient Inspire Paris, June 28, 2021 Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels, announced today that it has secured two of the largest insurance companies in the USA and France this month. Both organizations have selected Quadient Inspire, the leading Customer Communications Management (CCM) solution. In the United States, one of the top three U.S. property and casualty insurance firms has decided to adopt Quadient’s award-winning CCM solution as their platform for all claims communications. This contract is one of the largest deals in the CCM industry in the past 5 years, and contributes to solidify Quadient’s market leadership position, with now three of the...

Co-primary endpoint of the study objective response rate (ORR) was not met The board of directors is undergoing a strategic assessment regarding the future of the companyALLSCHWIL, Switzerland, June 28, 2021 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN), a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint. At the primary analysis, balixafortide plus eribulin showed no improvement in the objective response rate (ORR) compared with eribulin alone (13.0% versus...

Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitisDupixent is the first and only available systemic treatment for atopic dermatitis that has been studied in adults for up to 3 years in a Phase 3 trialPARIS and TARRYTOWN, N.Y. – June 28, 2021– Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use. Data from a single-arm Phase 3 open label extension (OLE) trial showed the long-term safety profile in adults with moderate-to-severe atopic dermatitis treated with Dupixent and observed up to...

Basel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021. Steven Baert, currently Chief People & Organization Officer, will step down from the Executive Committee of Novartis, effective June 30, 2021 after 15 years with the company and almost 8 years in position. Vicki Rawlinson, US Head People & Organization will lead the function ad-interim until Dr. Kowalski takes over. Dr. Kowalski is a senior drug development and regulatory executive with over 25 years of industry experience. He has successfully built and led Global Regulatory Affairs,...

Orphazyme A/SCompany announcement        No. 20/2021Inside informationCompany Registration No. 32266355–Significant headcount reduction of global workforce to free resources– -Changes to the Board of Directors- –Outlook for 2021 reiterated– Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC). The resulting cost savings include an approximate two thirds reduction in our global workforce. Orphazyme remains committed to pursuing regulatory approval in Europe and assessing a path forward for arimoclomol in the U.S. following receipt of a Complete Response Letter from the U.S. Food and Drug Administration...